Previous 10 | Next 10 |
Eton Pharmaceuticals (NASDAQ:ETON) has added ~4.6% in the pre-market after announcing a multi-year agreement with Tolmar Pharmaceuticals to co-promote ALKINDI SPRINKLE, an FDA-approved replacement therapy for Adrenocortical Insufficiency (AI) in children. Tolmar currently promo...
DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®. Eton will leverage Tolmar’s 62-person sales force and th...
Eton Pharmaceuticals (NASDAQ:ETON) and Azurity Pharmaceuticals announced the FDA approval of EPRONTIA (topiramate) oral solution, 25mg/mL. The regulator has approved EPRONTIA as monotherapy for patients aged two years and above with partial-onset or primary generalized tonic-clonic seizu...
DEER PARK, Ill. and WOBURN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EPRONTIA™ (topiramate) oral solution, 25mg/mL. EPRONTIA&...
DEER PARK, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating results on...
HCW Biologics (NASDAQ:HCWB) +102% after FDA greenlight for HCW9218 pancreatic cancer study InflaRx (NASDAQ:IFRX) +61% as Raymond James upgrades expecting price to quadruple LendingClub (NYSE:LC) +32% on Q3 earnings. DatChat (NASDAQ:DATS) +15% launches social...
Eton Pharmaceuticals (NASDAQ:ETON) is trading ~4.6% higher in the pre-market after the company announced the acquisition of marketing rights to a generic version of Carbaglu. The Abbreviated New Drug Application for the product, carglumic acid tablets, is owned by Novitium Phar...
DEER PARK, Ill., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. marketing rights to carglumic acid tablets. ...
Today, we revisit a small speciality pharmaceuticals company named Eton Pharmaceuticals. The stock was dinged in August thanks to some FDA actions, but the company has some potential positive catalysts on the horizon. A full investment analysis is presented in the paragraphs below...
Eton Pharmaceuticals, Inc. (ETON) Q2 2021 Results Conference Call August 16, 2021 04:30 PM ET Company Participants David Krempa - SVP, Business Development and IR Sean Brynjelsen - CEO Wilson Troutman - CFO Paul Stickler - SVP, Sales and Marketing Conference Call Participants Andrew D’...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...